@article{f14c807d5e2a45ee8305cfc5c9afcf83,
title = "2nd BASHH Oxford Diagnostics Course, November 2015",
keywords = "antibiotic, chlamydia (Chlamydia trachomatis), diagnosis, gonorrhoea (Neisseria gonorrhoeae), screening, Sexually transmitted infection, testing, treatment, trichomoniasis (Trichomonas vaginalis)",
author = "Patel, {R. R.} and White, {J. A.} and Menon-Johansson, {A. S.} and Sadiq, {S. T.} and Ross, {J. D.}",
note = "Funding Information: In his presentation, he noted that curable STIs, such as gonorrhoea, syphilis, chlamydia, TV and Mycoplasma genitalium, present a serious global health challenge. Recent systematic appraisals of evidence suggest that M. genitalium is a serious cause of reproductive health disease in women. Both gonorrhoea and M. genitalium infections are further compromised by high rates of AMR to multiple antibiotic classes, threatening simplified empirical therapy. Genotypic markers of antibiotic resistance to macro-lides in M. genitalium and to fluoroquinolones in gonorrhoea are all well-defined. Dr Sadiq{\textquoteright}s research team have shown that use of simple genotypic testing for fluoroquinolone resistance in gonorrhoea detected at genital and extra-genital anatomical sites is highly effective in predicting ciprofloxacin susceptibility. Such an approach is likely to achieve cure more often than relying on national epidemiological patterns and will achieve levels of cure achieved by first-line choice of antibiotic, beyond the threshold advised by the WHO. These developments allow for novel point-of-care (POC) AMR technologies to enhance empirical antibiotic therapy for genital discharge syndromes, enabling recycling of previously discarded antibiotics and potentially reducing spread of AMR. Novel molecular POC technologies, both hand-held and desktop-based for pathogen detection, will soon be available for use in UK clinics. The National Institute for Health Research funded Precise Project (www.pre ciseresearch.co.uk) is developing POC AMR tools for sexual health. The extended use of such technologies will help manage patients with genital discharge syndrome for whom empirical antibiotic selection has become increasingly challenging. The work is informed by public patient involvement at an early stage in design. Publisher Copyright: {\textcopyright} The Author(s) 2016.",
year = "2016",
doi = "10.1177/0956462416628782",
language = "English",
volume = "2016",
pages = "1--3",
journal = "International Journal of STD and AIDS",
issn = "0956-4624",
publisher = "SAGE Publications",
}